Bibliography
- Chang WN, Lu CH, Wu JJ, et al. Staphylococcus aureus meningitis in adults: a clinical comparison of infections caused by methicillin-resistant and methicillin-sensitive strains. Infection 2001;29:245-50
- Mekontso-Dessap A, Kirsch M, Brun-Buisson C, Loisance D. Poststernotomy mediastinitis due to Staphylococcus aureus: comparison of methicillin-resistant and methicillin-susceptible cases. Clin Infect Dis 2001;32:877-83
- Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339(8):520-32
- Petti CA, Fowler VG Jr. Staphylococcus aureus bacteremia and endocarditis. Infect Dis Clin North Am 2002;16(2):413-35
- Marks MI. Clinical significance of Staphylococcus aureus in cystic fibrosis. Infection 1990;18(1):53-6
- Hau T. Efficacy and safety of linezolid in the treatment of skin and soft tissue infections. Eur J Clin Microbiol Infect Dis 2002;21(7):491-8
- Sader HS, Jones RN, Silva JB; Sentry Participants Group. Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. Diagn Microbiol Infect Dis 2002;44(3):281-8
- Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. JAMA 1995;274:1706-13
- Mandal S, Berendt AR, Peacock SJ. Staphylococcus aureus bone and joint infection. J Infect 2002;44:143-51
- Fagon JY, Maillet JM, Novara A. Hospital-acquired pneumonia: methicillin resistance and intensive care unit admission. Am J Med 1998;104(5A):17S-23S
- Wagenvoort JH. Methicillin-resistant Staphylococcus aureus in ophthalmology, occurrence, sanitation measures and hygienic precautions. Dev Ophthalmol 2002;33:199-206
- Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine 2003;82(5):333-9
- Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36(5):592-8
- Lavin BS. Antibiotic cycling and marketing into the 21st century: a perspective from the pharmaceutical industry. Infect Control Hosp Epidemiol 2000;21(Suppl 1):S32-5
- Anderson D, Naimi TS, O'Boyle C, et al. Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia. In: Program and Abstracts of the IDSA 39th Annual Meeting; San Francisco, CA: Infectious Disease Society of America; 2001. p. 41
- Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin – United States, 1997. MMWR Morb Mort Wkly Rep 1997;46(33):765-6
- Centers for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin – Illinois, 1999. MMWR Morb Mort Wkly Rep 2000;48(51/52):1165-7
- Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis 2001;32(1):108-15
- Fridkin SK, Hageman J, McDougal LK, et al. Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997 – 2001. Clin Infect Dis 2003;36(4):429-39
- Hageman JC, Pegues DA, Jepson C, et al. Vancomycin-intermediate Staphylococcus aureus in a home health-care patient. Emerg Infect Dis 2001;7(6):1023-5
- Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40(1):135-6
- Rotun SS, McMath V, Schoonmaker DJ, et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999;5(1):147-9
- Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340(7):517-23
- Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340(7):493-501
- Centers for Disease Control and Prevention. Public health dispatch: vancomycin-resistant Staphylococcus aureus – Pennsylvania, 2002. MMWR Morb Mort Wkly Rep 2002;51(40):902
- Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin – United States, 2002. MMWR Morb Mort Wkly Rep 2002;51(26):565-7
- Kacica M, McDonald LC. Vancomycin-resistant Staphylococcus aureus – New York, 2004. MMWR Morb Mort Wkly Rep 2004;53(15):322-3
- Centers for Disease Control and Prevention. National Nosocomial Infectious Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85
- Gould IM. MRSA bacteraemia. Int J Antimicrob Agents 2007;30(Suppl 1):66-70
- Herman RA, Kee VR, Moores KG, Ross MB. Etiology and treatment of community-associated methicillin-resistant Staphylococcus aureus. Am J Health Syst Pharm 2008;65(3):219-25
- Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother 2005;55(Suppl 2):15-20
- Lacy CF, Armstrong LL, Goldman MP, Lance LL, editors. Lexi-drugs – comprehensive and specialty fields. Hudson, OH: Lexi-Comp, Inc.; 2008
- Candiani G, Abbondi M, Borgonovi M, et al. In-vitro and in vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother 1999;44(2):179-92
- Jones RN, Sader HS, Fritsche TR, Stilwell M. Comparative activity of dalbavancin tested against 7,771 isolates from the USA and Europe (2003). In: Proceedings of the 44th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 2004. p. 173
- McEvoy GK, editor. AHFS: drug information. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2007
- Bowker KE, Noel AR, MacGowan P. Antibacterial effect of dalbavancin against MSSA, MRSA and VISA in an in vitro pharmacokinetic system. In: Proceedings of the 44th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 2004. p. 24
- Jabes D, Candiani G, Romano G, et al. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model. Antimicrob Agents Chemother 2004;48(4):1118-23
- Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004;48(3):940-5
- Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003;37(10):1298-303
- Cavaleri M, Riva S, Valagussa A, et al. Pharmacokinetics and excretion of dalbavancin in the rat. J Antimicrob Chemother 2005;55(Suppl 2):31-5
- Bulgheroni A, Jabes D, Pollini W, et al. Dalbavancin (DAL) uptake by murine macrophages. In: Proceedings of the 44th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 2004. p. 35
- Andes DR, Craig WA. In vivo pharmacodynamic characterization of dalbavancin, (DAL) in the murine thigh infection model. In: Proceedings of the 44th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 2004. p. 39
- Bowker KE, Noel AR, MacGowan AP. Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system. J Antimicrob Chemother 2006;58:802-5
- Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 2007;51(5):1633-42
- Flamm RK, Draghi DC, Karlowsky JA, Sahm DF. Activity of dalbavancin against clinical isolates of staphylococci and streptococci from the US and Europe. In: Proceedings of the 44th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 2004. p. 173
- Gales AC, Sader HS, Jones RN. Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres. Clin Microbiol Infect 2005;11(2):95-100
- Lin G, Credito K, Ednie LM, Appelbaum PC. Antistaphylococcal activity of dalbavancin, an experimental glycopeptide. Antimicrob Agents Chemother 2005;49(2):770-2
- Lopez S, Hackbarth C, Romano G, et al. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother 2005;55(Suppl 2):21-4
- Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis 2004;48(2):137-43
- Stephen J, Jones RN, Sader HS, Fritsche TR. Worldwide assessment of dalbavancin (BI397) activity and spectrum (2002). In: Proceedings of the 43rd International Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: American Society of Microbiology; 2003. p. 2107
- Ednie L, Kelly LM, Smith K, et al. Antistaphylococcal activity of dalbavancin compared to those of six other agents. In: Proceedings of the 43rd International Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: American Society of Microbiology; 2003. p. 1631
- Mushtaq S, Warner M, Johnson AP, Livermore DM. Activity of dalbavancin against staphylococci and streptococci, assessed by BSAC and NCCLS agar dilution methods. J Antimicrob Chemother 2004;54(3):617-20
- Bozdogan B, Ednie L, Credito K, et al. Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. Antimicrob Agents Chemother 2004;48(12):4762-5
- Lin G, Smith K, Ednie L, Appelbaum PC. Antipneumococcal activity of dalbavancin compared to 9 other agents by MIC and time-kill. In: Proceedings of the 45th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 2005. p. 1740
- Heine HS, Bassett J, Miller L. In vitro and in vivo activity of dalbavancin (DAL) against Bacillus anthracis (BA). In: Proceedings of the 45th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 2005. p. 2079
- Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of dalbavancin and nine comparator agents against anaerobic Gram-positive species and corynebacteria. Antimicrob Agents Chemother 2003;47(6):1968-71
- Goldstein EJC, Citron DM. In vitro activity of dalbavancin and 12 other agents against 338 aerobic and anaerobic Gram-positive clinical strains solated from diabetic foot infections [DFI]. In: Proceedings of the 45th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 2005. p. 1749
- Johnson DM, Fritsche TR, Sader HS, Jones RN. Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions. Int J Antimicrob Agents 2006;27:557-60
- Goldstein BP, Draghi DC, Sheehan DJ, et al. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 2007;51(4):1150-4
- Dorr MB, Jabes D, Cavaleri M, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother 2005;55(Suppl 2):25-30
- Leighton A, Gottlieb AB, Dorr MB, et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 2004;48(3):940-5
- Dowell JA, Seltzer E, Buckwalter M, Marbury T. The pharmacokinetics of dalbavancin (DAL) in subjects with mild, moderate or severe hepatic impairment (HI). In: Proceedings of the 44th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 2004. p. 4
- Nicolau DP, Sun HK, Seltzer E, et al. Pharmacokinetics of dalbavancin in plasma and skin blister fluid. J Antimicrob Chemother 2007;60:681-4
- Solon EG, Dowell JA, Lee J, et al. Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand white rabbits. Antimicrob Agents Chemother 2007;51(8):3008-10
- Buckwalter M, Dowell JA. Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide. J Clin Pharmacol 2005;45:1279-87
- Mella S, Sepulveda M, Bello H, et al. Cloxacilin and vancomycin bacterial action against oxalicin-susceptible Staphylococcus aureus. Revista Med Chile 2001;129(2):224-6
- Nathwani D, Tillotson GS. Vancomycin for Staphylococcus aureus therapy of respiratory tract infections: the end of an era? Int J Antimicrob Agents 2003;21(6):521-4
- Fowler VG Jr, Sanders LL, Sexton DJ, et al. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis 1998;27(3):478-86
- Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999;29(5):1171-7
- Marr KA, Kong L, Fowler VG, et al. Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int 1998;54(5):1684-9
- Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin stucture infections. Clin Infect Dis 2005;41:1407-15
- Goldstein BP, Seltzer E, Flamm R, Sahm D. Dalbavancin (DAL) phase 3 skin and skin structure (SSSI) studies: pathogens and microbiological efficacy. In: Proceedings of the 45th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 2005. p. 1577
- Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens. Clin Infect Dis 2005;40:374-80
- Goldstein BP, Jones RN, Frische TR, Biedenbach DJ. Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections. Diag Microbiol Infect Dis 2006;54:83-7
- Seltzer E, Goldberg L, Krause D. Safety of dalbavancin (DAL) in a clinical development program. In: Proceedings of the 45th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology; 2005. p. 1576
- Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J Antimicrob Chemother 2006;58:627-31
- Pfizer receives approvable letter from FDA for dalbavancin. Pfizer Corporate News through Business Wire. 27 December 2007. Available from: http://mediaroom.pfizer.com/portal/site/pfizer/index.jsp?ndmViewId=news_view'newsId=20071221005672'newsLang=en [Last accessed 14 Mar 2008]